Northwestern Mutual Wealth Management Co. Raises Holdings in IDEXX Laboratories, Inc. $IDXX

Northwestern Mutual Wealth Management Co. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 63,503.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,444,445 shares of the company’s stock after acquiring an additional 1,442,174 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in IDEXX Laboratories were worth $977,210,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Empowered Funds LLC lifted its stake in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the second quarter worth $265,000. Jump Financial LLC lifted its stake in IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC acquired a new position in IDEXX Laboratories during the second quarter worth $164,000. Finally, Sei Investments Co. lifted its stake in IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 34,612 shares of company stock valued at $22,525,070 in the last three months. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Down 0.8%

Shares of NASDAQ IDXX opened at $528.79 on Friday. The stock has a market cap of $41.71 billion, a P/E ratio of 38.94, a PEG ratio of 3.10 and a beta of 1.58. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98. The business’s fifty day simple moving average is $572.08 and its 200-day simple moving average is $645.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. BTIG Research decreased their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.